Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 trial of valemetostat in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL)
    Meeting Abstract

    Erba, H. P.; Oluwole, O. O.; Bixby, D.; Rampal, R. K.; Fathi, A. T.; Paliwal, P.; Jin, J.; Inoue, A.; Daver, N.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed/refractory CLL/SLL: Results from BTK-naïve cohort in the phase 1/2 BRUIN study
    Meeting Abstract

    Wierda, W. G.; Eyre, T. A.; Lech-Maranda, E.; Roeker, L. E.; Patel, M.; Fukuhara, N.; Woyach, J. A.; Brown, J. R.; Patel, K.; Tam, C. S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Dose-optimization study of 3 starting doses of ponatinib: Long-term results from the OPTIC trial
    Meeting Abstract

    Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Pelabresib plus ruxolitinib combination therapy in jak inhibitor-naïve patients with myelofibrosis in the phase 3 MANIFEST-2 study: Preliminary evidence of bone marrow recovery
    Meeting Abstract

    Mascarenhas, J.; Rampal, R. K.; Vannucchi, A. M.; Gupta, V.; Oh, S. T.; Kuykendall, A. T.; Mesa, R.; Kiladjian, J. J.; Talpaz, M.; Kremyanskaya, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal or bone metastases in the phase II VISION trial
    Meeting Abstract

    Gasking, S.; Reinmuth, N.; Mazieres, J.; Popat, S.; Paz-Ares, L.; Hook, E.; Hatswell, A.; Vlassak, S.; Johne, A.; Vioix, H.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Longer-term safety and efficacy of selinexor maintenance therapy for patients with TP53wt advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
    Meeting Abstract

    Haluska, P.; Pérez-Fidalgo, J. A.; Vergote, I.; Hamilton, E.; de Giorgi, U.; Van Gorp, T.; Lübbe, K.; Zikan, M.; Helpman, L.; Miller, D. S.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Skin adverse events of anti-cancer treatments: An examination of drug-adverse events associations
    Meeting Abstract

    Khosrotehrani, K.; Salah, S.; Pages, C.; Lacouture, M. E.; Sibaud, V.
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy of selpercatinib by RET fusion partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 trials
    Meeting Abstract

    Solomon, B.; Drilon, A.; Park, K.; Novello, S.; Nadal, E.; Besse, B.; Peled, N.; Peterson, P.; Barker, S.; Szpurka, A. M.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, randomized, placebo-controlled, double-blind, multicenter trial of Selinexor in maintenance therapy for patients with p53 wild-type, advanced or recurrent endometrial carcinoma
    Meeting Abstract

    Webber, K.; Vergote, I.; Mirza, M. R.; Coleman, R.; Fidalgo, J. A. P.; Monk, B. J.; Valabrega, G.; Slomovitz, B.; Van Gorp, T.; Moore, K.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Updated tumor agnostic efficacy of selpercatinib in patients with RET fusion-positive solid tumors: LIBRETTO-001
    Meeting Abstract

    Ohe, Y.; Subbiah, V.; Sukrithan, V.; Robinson, B.; Deschler-Baier, B.; Iwasa, T.; Ohashi, K.; Goto, K.; Nishio, M.; Satouchi, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save